Temporal validation of the CT-PIRP prognostic model for mortality and renal replacement therapy initiation in chronic kidney disease patients.
CKD
Chronic kidney disease
Classification trees
Prognostic models
RRT inception
Renal disease
Renal outcomes
Temporal validation
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
17 05 2019
17 05 2019
Historique:
received:
01
12
2018
accepted:
18
04
2019
entrez:
19
5
2019
pubmed:
19
5
2019
medline:
1
9
2020
Statut:
epublish
Résumé
A classification tree model (CT-PIRP) was developed in 2013 to predict the annual renal function decline of patients with chronic kidney disease (CKD) participating in the PIRP (Progetto Insufficienza Renale Progressiva) project, which involves thirteen Nephrology Hospital Units in Emilia-Romagna (Italy). This model identified seven subgroups with specific combinations of baseline characteristics that were associated with a differential estimated glomerular filtration rate (eGFR) annual decline, but the model's ability to predict mortality and renal replacement therapy (RRT) has not been established yet. Survival analysis was used to determine whether CT-PIRP subgroups identified in the derivation cohort (n = 2265) had different mortality and RRT risks. Temporal validation was performed in a matched cohort (n = 2051) of subsequently enrolled PIRP patients, in which discrimination and calibration were assessed using Kaplan-Meier survival curves, Cox regression and Fine & Gray competing risk modeling. In both cohorts mortality risk was higher for subgroups 3 (proteinuric, low eGFR, high serum phosphate) and lower for subgroups 1 (proteinuric, high eGFR), 4 (non-proteinuric, younger, non-diabetic) and 5 (non-proteinuric, younger, diabetic). Risk of RRT was higher for subgroups 3 and 2 (proteinuric, low eGFR, low serum phosphate), while subgroups 1, 6 (non-proteinuric, old females) and 7 (non-proteinuric, old males) showed lower risk. Calibration was excellent for mortality in all subgroups while for RRT it was overall good except in subgroups 4 and 5. The CT-PIRP model is a temporally validated prediction tool for mortality and RRT, based on variables routinely collected, that could assist decision-making regarding the treatment of incident CKD patients. External validation in other CKD populations is needed to determine its generalizability.
Sections du résumé
BACKGROUND
A classification tree model (CT-PIRP) was developed in 2013 to predict the annual renal function decline of patients with chronic kidney disease (CKD) participating in the PIRP (Progetto Insufficienza Renale Progressiva) project, which involves thirteen Nephrology Hospital Units in Emilia-Romagna (Italy). This model identified seven subgroups with specific combinations of baseline characteristics that were associated with a differential estimated glomerular filtration rate (eGFR) annual decline, but the model's ability to predict mortality and renal replacement therapy (RRT) has not been established yet.
METHODS
Survival analysis was used to determine whether CT-PIRP subgroups identified in the derivation cohort (n = 2265) had different mortality and RRT risks. Temporal validation was performed in a matched cohort (n = 2051) of subsequently enrolled PIRP patients, in which discrimination and calibration were assessed using Kaplan-Meier survival curves, Cox regression and Fine & Gray competing risk modeling.
RESULTS
In both cohorts mortality risk was higher for subgroups 3 (proteinuric, low eGFR, high serum phosphate) and lower for subgroups 1 (proteinuric, high eGFR), 4 (non-proteinuric, younger, non-diabetic) and 5 (non-proteinuric, younger, diabetic). Risk of RRT was higher for subgroups 3 and 2 (proteinuric, low eGFR, low serum phosphate), while subgroups 1, 6 (non-proteinuric, old females) and 7 (non-proteinuric, old males) showed lower risk. Calibration was excellent for mortality in all subgroups while for RRT it was overall good except in subgroups 4 and 5.
CONCLUSIONS
The CT-PIRP model is a temporally validated prediction tool for mortality and RRT, based on variables routinely collected, that could assist decision-making regarding the treatment of incident CKD patients. External validation in other CKD populations is needed to determine its generalizability.
Identifiants
pubmed: 31101030
doi: 10.1186/s12882-019-1345-7
pii: 10.1186/s12882-019-1345-7
pmc: PMC6524315
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
177Références
Lancet. 2010 Jun 12;375(9731):2073-81
pubmed: 20483451
BMC Med Res Methodol. 2013 Mar 06;13:33
pubmed: 23496923
J Adv Nurs. 2014 Jun;70(6):1276-86
pubmed: 24237048
Diabetes Care. 2016 Jul;39(7):1259-66
pubmed: 27222502
Clin J Am Soc Nephrol. 2011 Aug;6(8):1879-86
pubmed: 21685022
Clin J Am Soc Nephrol. 2011 Apr;6(4):704-10
pubmed: 21273376
Nephrol Dial Transplant. 2014 Mar;29(3):603-10
pubmed: 24286974
BMJ Open. 2011 Dec 19;1(2):e000308
pubmed: 22184586
Am J Nephrol. 2012;36(1):1-10
pubmed: 22699366
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770
Hum Fertil (Camb). 2017 Jun;20(2):113-119
pubmed: 27894197
BMJ. 2013 Jan 29;346:f324
pubmed: 23360717
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):3-4
pubmed: 28028049
Kidney Int Rep. 2018 Jan 11;3(3):625-637
pubmed: 29854970
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):87-94
pubmed: 28028051
J Am Soc Nephrol. 2009 Dec;20(12):2625-30
pubmed: 19892934
Nephrol Dial Transplant. 2016 Jul;31(7):1122-30
pubmed: 26590389
Semin Nephrol. 2016 Jul;36(4):273-82
pubmed: 27475658
Transpl Int. 2015 May;28(5):519-28
pubmed: 25581324
J Clin Epidemiol. 2016 Jan;69:245-7
pubmed: 25981519
Clin J Am Soc Nephrol. 2011 Aug;6(8):1805-6
pubmed: 21784817
Am J Kidney Dis. 2017 Apr;69(4):514-520
pubmed: 27693260
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Int Urol Nephrol. 2009 Dec;41(4):977-82
pubmed: 19578968
Arch Intern Med. 2004 Mar 22;164(6):659-63
pubmed: 15037495
J Nephrol. 2019 Jun;32(3):417-427
pubmed: 30659519
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
Eur Heart J. 2014 Nov 7;35(42):2936-41
pubmed: 24711436
Ann Behav Med. 2003 Dec;26(3):172-81
pubmed: 14644693
Int J Cardiol. 2016 May 1;210:125-32
pubmed: 26942330
Am J Nephrol. 2012;36(1):41-9
pubmed: 22699706
J Am Soc Nephrol. 2009 Dec;20(12):2617-24
pubmed: 19892932
Ann Intern Med. 2013 Apr 16;158(8):596-603
pubmed: 23588748
Nephrol Dial Transplant. 2008 Feb;23(2):549-55
pubmed: 18065826
J Thorac Oncol. 2016 Apr;11(4):573-82
pubmed: 26776867
Clin Epidemiol. 2017 Sep 05;9:451-464
pubmed: 28919820
Stat Med. 1996 Dec 30;15(24):2763-80
pubmed: 8981685